Company Fundamentals\Company Profile
A Wright Investors' Service Research Report:
Regeneron Pharmaceuticals Incorporated
440 Wheelers Farms Road
Milford, CT 06461 U.S.A.
COMPANY PROFILE
Figures in U.S. Dollars
Wright Quality Rating:BBNN Key Data
Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Ticker:
Regeneron discovers, develops, and commercializes pharmaceutical products for the REGN
treatment of serious medical conditions. As of December 31, 2010, the Company had
one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which 2010 Sales:
is available for prescription in the United States for the treatment of Cryopyrin-
459,074,000
Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory
Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and
older. Its late stage programs are VEGF Trap-Eye (aflibercept ophthalmic solution), Major Industry:
which is being developed for the prevention and treatment of serious eye diseases; Drugs, Cosmetics & Health
ARCALYST, which is being developed for the prevention of gout flares in patients Care
initiating uric acid-lowering treatment, and aflibercept (VEGF Trap), which is being
developed in oncology in collaboration with the sanofi-aventis Group. Sub Industry:
Stock Chart Officers Ethical Drug Manufacturers
Chairman
Dr. P. Roy Vagelos Country:
United States
President & Chief Executive
Dr. Leonard S. Schleifer Currency:
U.S. Dollars
Senior Vice President
Finance, Chief Financial
Fiscal Year Ends:
Officer & Treasurer
Murray A. Goldberg December
Employees
1,395
Exchanges:
NAS
Share Type:
Common
Stock Price (7/29/2011): 53.06